← 返回

肿瘤浸润性 T 细胞的代谢多样性作为抗免疫治疗的靶点

英文原题:Metabolic diversity of tumor-infiltrating T cells as target for anti-immune therapeutics.

查看英文原题

Metabolic diversity of tumor-infiltrating T cells as target for anti-immune therapeutics.

PubMed 2023/09/21(内容时间) Cancer Immunol Immunother Q1 · IF 5.8(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

肿瘤浸润性T细胞是调控肿瘤微环境的有前景的药物靶点。然而,作为癌症免疫治疗的核心靶点,肿瘤浸润性T淋巴细胞在肿瘤微环境和癌症类型之间表现出相当大的异质性和动态变化,这可能从根本上影响癌症生长、转移、复发以及对临床药物的反应。T细胞异质性不仅指亚群组成,还指T细胞不同的代谢状态。与已被充分认识的肿瘤浸润性T细胞组成多样性相比,T细胞的代谢多样性在精准免疫治疗中值得更多关注。单细胞测序技术使得肿瘤整体的全景拼接成为可能,部分原因在于其能够在单细胞分辨率下展示肿瘤浸润性T细胞的代谢相关基因表达谱。因此,我们在此讨论由肿瘤微环境触发的T细胞代谢重编程以及代谢靶向药物的潜在应用。本简要综述还讨论了不同癌症类型中肿瘤浸润性T细胞的代谢通路依赖性。

展开英文摘要原文

Tumor-infiltrating T cells are promising drug targets to modulate the tumor microenvironment.

However, tumor-infiltrating T lymphocytes, as central targets of cancer immunotherapy, show considerable heterogeneity and dynamics across tumor microenvironments and cancer types that may fundamentally influence cancer growth, metastasis, relapse, and response to clinical drugs. The T cell heterogeneity not only refers to the composition of subpopulations but also divergent metabolic states of T cells.

Comparing to the diversity of tumor-infiltrating T cell compositions that have been well recognized, the metabolic diversity of T cells deserves more attention for precision immunotherapy. Single-cell sequencing technology enables panoramic stitching of the tumor bulk, partly by showing the metabolic-related gene expression profiles of tumor-infiltrating T cells at a single-cell resolution.

Therefore, we here discuss T cell metabolism reprogramming triggered by tumor microenvironment as well as the potential application of metabolic targeting drugs. The tumor-infiltrating T cells metabolic pathway addictions among different cancer types are also addressed in this brief review.

论文信息

作者
Li P、Li F、Zhang Y、Yu X、Li J
第一作者单位
Affiliated Hospital of Weifang Medical University, School of Clinical Medicine, Weifang Medical University, Weifang, 262700, China.China
通讯作者单位
Affiliated Hospital of Weifang Medical University, School of Clinical Medicine, Weifang Medical University, Weifang, 262700, China. jingjingli.md.phd@gmail.com.China
文献类型
综述
期刊
Cancer immunology, immunotherapy : CII2023 Nov
原文标识
PubMed 37733059 · DOI 10.1007/s00262-023-03540-1